Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation

Larson, Mark K.; Tormoen, Garth W.; Weaver, Lucinda J.; Luepke, Kristen J.; Patel, Ishan; Hjelmen, Carl E.; Ensz, Nicole M.; McComas, Leah S.; McCarty, Owen J. T.

doi:10.1152/ajpcell.00174.2012

Cited by 53 publications

(44 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very recent studies have suggested that exogenous modification of platelet membranes by omega-3 fatty acids results in decreased platelet procoagulant activity and thrombus formation. 22 Platelets show less aggregation and activation in healthy subjects who are taking omega-3 supplements. 23 Population-based studies suggest that for an association with lower fibrinogen levels to be seen, fish oil consumption must be high, achieving red blood cell levels similar to those seen on pharmacologic therapy.…”

Section: Discussionmentioning

confidence: 99%

A Double-Blind Randomized Trial of Fish Oil to Lower Triglycerides and Improve Cardiometabolic Risk in Adolescents

Gidding¹,

Prospero²,

Hossain³

et al. 2014

The Journal of Pediatrics

View full text Add to dashboard Cite

Objectives To determine the efficacy of 4 g/day fish oil to lower triglycerides and impact lipoprotein particles, inflammation, insulin resistance, coagulation, and thrombosis. Study design Participants (n = 42, age 14 ± 2 years) with hypertriglyceridemia and low-density lipoprotein (LDL) cholesterol <160 mg/dL were enrolled in a randomized, double-blind, crossover trial comparing 4 g of fish oil daily with placebo. Treatment interval was 8 weeks with a 4-week washout. Lipid profile, lipoprotein particle distribution and size, glucose, insulin, high-sensitivity C-reactive protein, interleukin-6, fibrinogen, plasminogen activator inhibitor-1, and thrombin generation were measured. Results Baseline lipid profile was total cholesterol 194 (5.4) mg/dL (mean [SE]), triglycerides 272 (21) mg/dL, high-density lipoprotein cholesterol 39 (1) mg/dL, and LDL cholesterol 112 (3.7) mg/dl. LDL particle number was 1614 (60) nmol/L, LDL size was 19.9 (1.4) nm, and large very low-density lipoprotein/chylomicron particle number was 9.6 (1.4) nmol/L. Triglycerides decreased on fish oil treatment but the difference was not significant compared with placebo (−52 ± 16 mg/dL vs −16 ± 16 mg/dL). Large very low-density lipoprotein particle number was reduced (−5.83 ± 1.29 nmol/L vs −0.96 ± 1.31 nmol/L; P < .0001). There was no change in LDL particle number or size. There was a trend towards a lower prothrombotic state (lower fibrinogen and plasminogen activator inhibitor-1; .10 > P > .05); no other group differences were seen. Conclusions In children, fish oil (4 g/day) lowers triglycerides slightly and may have an antithrombotic effect but has no effect on LDL particles.

show abstract

Section: Discussionmentioning

confidence: 99%

A Double-Blind Randomized Trial of Fish Oil to Lower Triglycerides and Improve Cardiometabolic Risk in Adolescents

Gidding¹,

Prospero²,

Hossain³

et al. 2014

The Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…Potential mechanisms whereby omega-3 PUFAs may regulate dopamine include reducing cortical MAO-B activity, thereby decreasing the degradation of monoamines (Chalon et al, 1998); improving dopamine neuron survival (Ahmad et al, 2008); and influencing lipid rafts (Rockett et al, 2011; Rockett et al, 2012; Williams et al, 2012; Larson et al, 2013), that, in turn, may upregulate D1 receptors (Yu et al, 2004) and mediate D2 receptor endocytosis (Genedani et al, 2005). …”

Section: Discussionmentioning

confidence: 99%

Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder

Sublette

Galfalvy

Hibbeln

et al. 2013

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

Dopaminergic function is thought to be altered in major depression and, in animal studies, is reduced in omega-3 PUFA deficiency states. Therefore we studied PUFAs and resting prolactin, a marker for dopaminergic tone, and cerebrospinal fluid homovanillic acid (HVA), the chief dopamine metabolite. In medication-free adults (n=23) with DSM-IV major depressive disorder (MDD), we measured plasma phospholipid levels of omega-3 PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), the omega-6 PUFA arachidonic acid (AA), and plasma prolactin levels before and after administration of dl-fenfluramine (FEN). In a subset of patients (n=14), cerebrospinal fluid levels of HVA and the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were obtained through lumbar puncture. Baseline prolactin was negatively correlated with omega-3 PUFAs (logDHA, F[1,21]=20.380, p<0.001; logEPA, F[1,21]=10.051, p=0.005) and positively correlated with logAA:DHA (F[1,21]=15.263, p=0.001), a measure of omega-6/omega-3 balance. LogDHA was negatively correlated with CSF HVA (Spearman’s rho=−0.675, p=0.008) but not 5-HIAA (Spearman’s rho=−0.143, p=0.626) after controlling for sex and HVA – 5-HIAA correlation. PUFAs did not predict the magnitude of the FEN-stimulated change in prolactin, considered to be a serotonin effect. The robust relationship of omega-3 PUFAs with dopaminergic but not serotonergic indices suggests that omega-6/omega-3 balance may impact depression pathophysiology through effects on the dopaminergic system.

show abstract

“…The inhibitory effect of O3FA on pro-coagulant platelet- and monocyte-derived microparticles has also been described in specific situations 21,22 . Additionally, EPA and DHA can decrease platelet-mediated thrombin generation, thereby acting indirectly on the coagulation cascade 23 . O3FA are also known to potentiate plasma fibrinolysis by increasing the levels of vascular plasminogen activator and reducing the levels of its inhibitors 24 .…”

Section: Discussionmentioning

confidence: 99%

Risk of post-procedural bleeding in children on intravenous fish oil

Nandivada

Anez‐Bustillos

O’Loughlin

et al. 2017

The American Journal of Surgery

View full text Add to dashboard Cite

Background Intestinal failure-associated liver disease (IFALD) can be treated with parenteral fish oil (FO) monotherapy, but practitioners have raised concerns about a potential bleeding risk. This study aims to describe the incidence of clinically significant post-procedural bleeding (CSPPB) in children receiving FO monotherapy. Methods A retrospective chart review was performed on patients at our institution treated with intravenous FO for IFALD. CSPPB was defined as bleeding leading to re-operation, transfer to the intensive care unit, re-admission, or death, up to one month after any invasive procedure. Results From 244 patients reviewed, 183 underwent ≥1 invasive procedure (n=732). Five (0.68%, 95% CI 0.22–1.59%) procedures resulted in CSPPB. FO therapy was never interrupted. No deaths occurred. Conclusions Findings suggest that FO therapy is safe, with a CSPPB risk no greater than that reported in the general population. O3FA should not be held in preparation for procedures or in the event of bleeding.

show abstract

Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation

Cited by 53 publications

References 34 publications

A Double-Blind Randomized Trial of Fish Oil to Lower Triglycerides and Improve Cardiometabolic Risk in Adolescents

A Double-Blind Randomized Trial of Fish Oil to Lower Triglycerides and Improve Cardiometabolic Risk in Adolescents

Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder

Risk of post-procedural bleeding in children on intravenous fish oil

Contact Info

Product

Resources

About